INMB

8.03

2.29% 0.18

Handel nachbörslich: 8.03

Inmune Bio Inc (INMB)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$7.85

Offen:

$7.74

24-Stunden-Volumen:

232.41K

Relative Volume:

0.66

Marktkapitalisierung:

$178.04M

Einnahmen:

$155.00K

Nettoeinkommen (Verlust:

$-30.01M

KGV:

-4.8084

EPS:

-1.67

Netto-Cashflow:

$-11.98M

1W Leistung:

-6.52%

1M Leistung:

+0.12%

6M Leistung:

+17.57%

1J Leistung:

-32.06%

1-Tages-Spanne:

$7.30

$8.135

1-Wochen-Bereich:

$7.30

$8.69

52-Wochen-Spanne:

$4.32

$13.30

Inmune Bio Inc Stock (INMB) Company Profile

Firmenname

Inmune Bio Inc

Sektor

Healthcare (1185)

Branche

Biotechnology (679)

Telefon

(858) 964-3720

Adresse

225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA

Mitarbeiter

Twitter

@INmuneBio

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

INMB's Discussions on Twitter

Vergleichen Sie INMB mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
INMB Inmune Bio Inc	8.03	178.04M	155.00K	-30.01M	-11.98M	-1.67
VRTX Vertex Pharmaceuticals Inc	479.79	123.21B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	698.74	76.39B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	624.67	37.96B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	246.75	31.94B	2.25B	-278.16M	-42.59M	-2.17
ONC Beone Medicines Ltd Adr	271.80	29.00B	3.32B	-860.46M	-1.04B	-8.32

Inmune Bio Inc Stock (INMB) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-01-28	Eingeleitet	Rodman & Renshaw	Buy
2024-10-21	Eingeleitet	Alliance Global Partners	Buy
2024-09-27	Eingeleitet	Raymond James	Outperform
2024-08-22	Eingeleitet	Scotiabank	Sector Outperform
2023-06-01	Eingeleitet	Robert W. Baird	Outperform
2022-05-24	Herabstufung	B. Riley Securities	Buy → Neutral
2021-07-07	Bestätigt	Maxim Group	Buy
2021-04-21	Eingeleitet	B. Riley Securities	Buy
2021-01-22	Bestätigt	Maxim Group	Buy
2020-09-01	Eingeleitet	BTIG Research	Buy
2020-07-15	Bestätigt	H.C. Wainwright	Buy

Alle ansehen

Inmune Bio Inc Aktie (INMB) Neueste Nachrichten

Feb 27, 2025

Is INmune Bio (NASDAQ:INMB) A Risky Investment? - Simply Wall St

Feb 27, 2025

Feb 24, 2025

INmune Delivers Impressive 100% Gain In Just 3 MonthsIs There More Room To Run? - RTTNews

Feb 24, 2025

Feb 23, 2025

Learn to Evaluate (INMB) using the Charts - Stock Traders Daily

Feb 23, 2025

Feb 21, 2025

INmune Bio, Inc. to Host Earnings Call - ACCESS Newswire

Feb 21, 2025

Feb 20, 2025

INmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28% - Yahoo Finance

Feb 20, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter

Feb 20, 2025

Feb 18, 2025

INmune Bio, Inc. (NASDAQ:INMB) Sees Significant Growth in Short Interest - Defense World

Feb 18, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Analysts - Defense World

Feb 18, 2025

Feb 16, 2025

INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Maxim Group Analyst Says - MarketBeat

Feb 16, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Brokerages - Defense World

Feb 16, 2025

INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Average Price Target from Brokerages - MarketBeat

Feb 16, 2025

Feb 14, 2025

INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Scotiabank Analyst Says - MarketBeat

Feb 14, 2025

Feb 13, 2025

Raymond James raises INmune Bio stock target to $23 By Investing.com - Investing.com Nigeria

Feb 12, 2025

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer - The Manila Times

Feb 12, 2025

INmune Bio Inc. Reports Safe Phase 1 Results for INKmune™ in mCRPC, Opens Phase 2 Enrollment - Nasdaq

Feb 12, 2025

Inmune Bio’s Strategic Advancements and Promising Clinical Trials Justify Buy Rating - TipRanks

Feb 12, 2025

INmune Bio’s CORDStrom shows promise in RDEB treatment By Investing.com - Investing.com Nigeria

Feb 12, 2025

Scotiabank raises INmune Bio stock target to $23 on new therapy - MSN

Feb 12, 2025

INmune Bio Inc. Discloses New Investor and Webinar PresentationsOn February 10, 2025, INmune Bio Inc. (NASDAQ: INMB) submitted an 8-K form to the Securities and Exchange Commission, revealing that the company had developed an Investor Presentati - Defense World

Feb 12, 2025

Feb 11, 2025

INmune Bio's CORDStrom shows promise in RDEB treatment - MSN

Feb 11, 2025

Market Insight: INmune Bio Inc (INMB)’s Notable Drop, Closing at 9.12 - The Dwinnex

Feb 11, 2025

Scotiabank raises INmune Bio stock target to $23 on new therapy By Investing.com - Investing.com South Africa

Feb 11, 2025

Feb 10, 2025

BLA Submission Planned for CORDStrom in RDEB - MD Magazine

Feb 10, 2025

Inmune Bio Secures License Agreement for CORDStrom Data - TipRanks

Feb 10, 2025

INmune Bio to Seek Approval of Skin Disorder Treatment in US, UK, Europe -February 10, 2025 at 10:26 am EST - Marketscreener.com

Feb 10, 2025

Inmune Bio Completes Phase 2 Trial for CORDStrom - TipRanks

Feb 10, 2025

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) - Markets Insider

Feb 10, 2025

INmune Bio's CORDStrom shows promise in RDEB treatment By Investing.com - Investing.com South Africa

Feb 10, 2025

INmune Bio (INMB) to Submit FDA Biologics License Application Seeking Approval of CORDStrom - StreetInsider.com

Feb 10, 2025

Feb 07, 2025

Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Expands By 7.0% - MarketBeat

Feb 07, 2025

Feb 05, 2025